Therapy of Experimental Herpes Simplex Encephalitis with Aciclovir in Mice

AUTOR(ES)

Park, No-Hee

RESUMO

This report is concerned with the capacities of aciclovir to protect mice challenged intracerebrally with multiple lethal doses of type 1 herpes simplex virus and to control multiplication of this virus in the brain. With treatment initiated 12 h after inoculation and continued for 4 consecutive days, aciclovir administered subcutaneously in daily doses ranging from 40 to 100 mg/kg led to 21-day survival rates of from 33 to 73% and reduced virus titers by 1 to ½ × 4 logs on postchallenge day 8. The therapeutic accomplishments of the 100-mg/kg doses of aciclovir were comparable to those of 1,000-mg/kg doses of vidarabine (9-β-d-arabinofuranosyladenine); however, as measured by impact on body weight, aciclovir was better tolerated than vidarabine at these similarly effective doses.

Documentos Relacionados

• Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.
• Effect of treatment with 1-beta-D-arabinofuranosylthymine of experimental encephalitis induced by herpes simplex virus in mice.
• Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients
• Encephalitis resulting from reactivation of latent herpes simplex virus in mice.
• Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin.